Zentalis Pharmaceuticals (ZNTL) Research & Development (2019 - 2026)

Zentalis Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $28.7 million for Q1 2026.

• In Q1 2026, Research & Development rose 5.39% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $108.8 million (down 25.21% YoY), while the FY2025 annual figure was $107.3 million, down 36.05% from the prior year.
• Research & Development was $28.7 million for Q1 2026 at Zentalis Pharmaceuticals, down from $29.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $51.6 million in Q4 2023 to a low of $23.0 million in Q3 2025.
• Historically, Research & Development has averaged $39.2 million across 5 years, with a median of $42.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Research & Development advanced 26.94% in 2023, then sank 45.05% in 2025.
• A 5-year view of Research & Development shows it stood at $40.6 million in 2022, then rose by 26.94% to $51.6 million in 2023, then slumped by 36.05% to $33.0 million in 2024, then dropped by 10.57% to $29.5 million in 2025, then decreased by 2.62% to $28.7 million in 2026.
• The last three Research & Development figures came in at $28.7 million (Q1 2026), $29.5 million (Q4 2025), and $23.0 million (Q3 2025), per Business Quant data.